RISUG

Alternative Name: Reversible inhibition of sperm under guidance (RISUG)

Description: Partial vasal occulsion through injection of styrene/maleic anhydride (SMA) and dimethyl sulfoxide (DMSO) in vas lumen.

Product Details

User: Male

Hormonal: No

Delivery Method: Vas Deferens

Duration Type: Long-acting

Duration: 8 years

Multipurpose Preventive Technology (MPT): Yes

Status Details

Developer: Indian Council for Medical Research, Indian Institute of Technology, Kharagpur

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Phase III

Active Development: Yes

Additional Information

References:
  • Lohiya NK, et al. (2014) RISUG: An intravasal injectable male contraceptive. Indian J Med Res. 140(Suppl 1): S6-S72.

  • Guha SK. (2005) RISUG (reversible inhibition of sperm under guidance)--an antimicrobial as male vas deferens implant for HIV free semen. Med Hypotheses. 65(1): 64-4.

  • Ansari A, et al. (2017). Contraception with RISUG® and functional reversal through DMSO and NaHCO3 in male rabbits. Asian J Androl. 19(4): 389–395.

  • Lohiya, N., Manivannan, B., & Mishra, P. (1998). Ultrastructural Changes in the Spermatozoa of Langur Monkeys Presbytis entellus entellus After Vas Occlusion With Styrene Maleic Anhydride. Contraception, 57(2), 125-132.

  • Subramanian, B., Rameshbabu, A. P., Ghosh, K., Jha, P. K., Jha, R., Murugesan, S., . . . Guha, S. K. (2019). Impact of styrene maleic anhydride (SMA) based hydrogel on rat fallopian tube as contraceptive implant with selective antimicrobial property. Materials Science and Engineering: C,94, 94-107.

Vertical Tabs

Print